Henry Schein (NASDAQ:HSIC) Price Target Raised to $88.00

Henry Schein (NASDAQ:HSICFree Report) had its price target increased by JPMorgan Chase & Co. from $82.00 to $88.00 in a research report released on Wednesday morning, Benzinga reports. They currently have an overweight rating on the stock.

Several other equities analysts have also weighed in on HSIC. UBS Group reduced their target price on shares of Henry Schein from $82.00 to $75.00 and set a neutral rating on the stock in a report on Tuesday, November 14th. Piper Sandler boosted their price objective on shares of Henry Schein from $78.00 to $86.00 and gave the stock an overweight rating in a report on Monday, February 26th. SVB Leerink assumed coverage on shares of Henry Schein in a report on Monday, February 26th. They issued a market perform rating and a $78.00 price objective on the stock. Morgan Stanley cut their price objective on shares of Henry Schein from $69.00 to $65.00 and set an underweight rating on the stock in a report on Tuesday, November 14th. Finally, StockNews.com lowered shares of Henry Schein from a buy rating to a hold rating in a report on Monday, December 4th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Henry Schein has an average rating of Hold and an average target price of $81.09.

View Our Latest Research Report on HSIC

Henry Schein Stock Performance

NASDAQ:HSIC opened at $74.76 on Wednesday. The company has a current ratio of 1.67, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $9.61 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 1.86 and a beta of 0.87. The firm’s fifty day simple moving average is $75.20 and its 200 day simple moving average is $72.84. Henry Schein has a twelve month low of $60.01 and a twelve month high of $85.75.

Henry Schein (NASDAQ:HSICGet Free Report) last posted its earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.04). The business had revenue of $3.02 billion for the quarter, compared to analyst estimates of $3 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The business’s revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.21 EPS. As a group, equities research analysts expect that Henry Schein will post 5.08 earnings per share for the current fiscal year.

Insider Transactions at Henry Schein

In related news, CEO Stanley M. Bergman sold 13,962 shares of the business’s stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $75.14, for a total transaction of $1,049,104.68. Following the completion of the sale, the chief executive officer now owns 168,633 shares of the company’s stock, valued at approximately $12,671,083.62. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Stanley M. Bergman sold 13,962 shares of the business’s stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $75.14, for a total transaction of $1,049,104.68. Following the completion of the sale, the chief executive officer now owns 168,633 shares of the company’s stock, valued at approximately $12,671,083.62. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bradford C. Connett sold 11,238 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $74.02, for a total transaction of $831,836.76. Following the sale, the chief executive officer now directly owns 57,831 shares of the company’s stock, valued at approximately $4,280,650.62. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Henry Schein by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 15,331,533 shares of the company’s stock worth $1,336,756,000 after purchasing an additional 214,846 shares during the last quarter. JPMorgan Chase & Co. grew its position in Henry Schein by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company’s stock worth $353,898,000 after purchasing an additional 53,506 shares during the last quarter. American Century Companies Inc. grew its position in Henry Schein by 7.3% in the 3rd quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock worth $350,392,000 after purchasing an additional 322,649 shares during the last quarter. Boston Partners grew its position in Henry Schein by 144.1% in the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after purchasing an additional 1,556,831 shares during the last quarter. Finally, Morgan Stanley grew its position in Henry Schein by 143.4% in the 4th quarter. Morgan Stanley now owns 2,337,890 shares of the company’s stock worth $186,727,000 after purchasing an additional 1,377,207 shares during the last quarter. Institutional investors own 93.31% of the company’s stock.

About Henry Schein

(Get Free Report)

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

See Also

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.